Terminal Deletion of 11q with Significant Late-Onset Combined Immune Deficiency
- 15 November 2013
- journal article
- case report
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 34 (1) , 114-118
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapyLeukemia & Lymphoma, 2013
- Review of Ets1 structure, function, and roles in immunityCellular and Molecular Life Sciences, 2013
- Newborn Screening for Severe Combined Immunodeficiency; The Wisconsin Experience (2008–2011)Journal of Clinical Immunology, 2011
- Chromosome 22q11.2 Deletion Syndrome (DiGeorge Syndrome/Velocardiofacial Syndrome)Medicine, 2011
- Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapyEuropean Journal of Haematology, 2010
- Ets1 is required for proper migration and differentiation of the cardiac neural crestDevelopment, 2010
- Clinical and molecular‐cytogenetic evaluation of a family with partial Jacobsen syndrome without thrombocytopenia caused by an ∼5 Mb deletion del(11)(q24.3)American Journal of Medical Genetics Part A, 2008
- Effects of Ageing and Gender on Naturally Acquired Antibodies to Pneumococcal Capsular Polysaccharides and Virulence-Associated ProteinsClinical and Vaccine Immunology, 2008
- The 11q terminal deletion disorder: A prospective study of 110 casesAmerican Journal of Medical Genetics Part A, 2004
- Clinical and molecular characterization of patients with distal 11q deletions.1995